EA201390917A1 - Дигетероарильные соединения в качестве ингибиторов vps34 - Google Patents
Дигетероарильные соединения в качестве ингибиторов vps34Info
- Publication number
- EA201390917A1 EA201390917A1 EA201390917A EA201390917A EA201390917A1 EA 201390917 A1 EA201390917 A1 EA 201390917A1 EA 201390917 A EA201390917 A EA 201390917A EA 201390917 A EA201390917 A EA 201390917A EA 201390917 A1 EA201390917 A1 EA 201390917A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- vps34
- digeteroarylic
- connections
- inhibitors
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Настоящее изобретение относится к новым способам лечения заболевания или нарушения, характеризующегося повышенной активностью Vps34, и к соединению в качестве ингибиторов Vps34, в частности к соединению формулы Iили его фармацевтически приемлемой соли, и также к способам лечения заболевания, нарушения или синдрома, связанного с ингибированием Vps34, в частности гиперпролиферативных заболеваний. Кроме того, настоящее изобретение относится к фармацевтическим композициям, содержащим соединения формулы I и их фармацевтически приемлемые соли.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061425416P | 2010-12-21 | 2010-12-21 | |
PCT/IB2011/055772 WO2012085815A1 (en) | 2010-12-21 | 2011-12-19 | Bi-heteroaryl compounds as vps34 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201390917A1 true EA201390917A1 (ru) | 2013-12-30 |
Family
ID=45509576
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201390917A EA201390917A1 (ru) | 2010-12-21 | 2011-12-19 | Дигетероарильные соединения в качестве ингибиторов vps34 |
Country Status (11)
Country | Link |
---|---|
US (2) | US8685993B2 (ru) |
EP (1) | EP2655340B1 (ru) |
JP (1) | JP2014500308A (ru) |
KR (1) | KR20130130030A (ru) |
CN (1) | CN103270026A (ru) |
AU (1) | AU2011346567A1 (ru) |
BR (1) | BR112013015449A2 (ru) |
CA (1) | CA2822565A1 (ru) |
EA (1) | EA201390917A1 (ru) |
MX (1) | MX2013007336A (ru) |
WO (1) | WO2012085815A1 (ru) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013040013A2 (en) * | 2011-09-13 | 2013-03-21 | Brookhaven Science Associates, Llc | Bimetallic catalysts for co2 hydrogenation and h2 generation from formic acid and/or salts thereof |
JP5896539B2 (ja) * | 2012-01-27 | 2016-03-30 | 国立研究開発法人産業技術総合研究所 | ギ酸の脱水素化触媒、水素製造方法、重水素ガスまたは重水素化水素の製造方法 |
RU2653735C2 (ru) * | 2012-10-18 | 2018-05-14 | Ниссин Фудз Холдингз Ко., Лтд. | Средство, усиливающее соленый вкус, и способ изготовления, и способ усиления соленого вкуса |
WO2014167008A1 (en) | 2013-04-12 | 2014-10-16 | Bayer Cropscience Ag | Novel triazolinthione derivatives |
EA028812B1 (ru) | 2013-04-12 | 2018-01-31 | Байер Кропсайенс Акциенгезельшафт | Триазольные производные |
JP2017502092A (ja) | 2014-01-14 | 2017-01-19 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | ヘテロアリール及びその使用 |
ES2908042T3 (es) | 2014-01-14 | 2022-04-27 | Takeda Pharmaceuticals Co | Heteroarilos y usos de los mismos |
MX2017012709A (es) | 2015-04-02 | 2017-11-23 | Bayer Cropscience Ag | Nuevos derivados de imidazolilmetilo 5-sustituidos. |
JP2018511608A (ja) | 2015-04-02 | 2018-04-26 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 殺真菌剤としてのトリアゾール誘導体 |
HUE051059T2 (hu) | 2016-02-19 | 2021-03-01 | Sprint Bioscience Ab | Rák és diabétesz kezelésére szolgáló 6-heterociklusos-4-morfolin-4-ilpiridin-2-on vegyületek |
US11077113B2 (en) * | 2016-02-19 | 2021-08-03 | Sprint Bioscience Ab | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
EA201990690A1 (ru) | 2016-09-13 | 2019-10-31 | Комбинации активных соединений, содержащие производное 5-замещенного имидазола | |
WO2018060073A1 (en) | 2016-09-29 | 2018-04-05 | Bayer Cropscience Aktiengesellschaft | Novel 5-substituted imidazole derivatives |
US20200045972A1 (en) | 2016-09-29 | 2020-02-13 | Bayer Cropscience Aktiengesellschaft | Novel 5-substituted imidazolylmethyl derivatives |
WO2018060074A1 (en) | 2016-09-29 | 2018-04-05 | Bayer Cropscience Aktiengesellschaft | Novel 5-substituted imidazolylmethyl derivatives |
LT3672941T (lt) | 2017-08-23 | 2022-07-11 | Sprint Bioscience Ab | Piridilpiridono junginiai |
TWI785102B (zh) | 2017-08-23 | 2022-12-01 | 瑞典商斯普林特生物科技公司 | 吡啶胺-吡啶酮及嘧啶胺-吡啶酮化合物 |
PT3672962T (pt) | 2017-08-23 | 2022-04-12 | Sprint Bioscience Ab | Compostos de morfolinilpiridona |
AU2018321135B2 (en) | 2017-08-23 | 2023-11-23 | Sprint Bioscience Ab | Azaindolylpyridone and diazaindolylpyridone compounds |
EP3710432A1 (en) | 2017-11-13 | 2020-09-23 | Bayer Aktiengesellschaft | Tetrazolylpropyl derivatives and their use as fungicides |
TW202120495A (zh) * | 2019-08-02 | 2021-06-01 | 美商愛彼特生物製藥股份有限公司 | 經取代環丙基—2,2'—聯嘧啶基化合物、其類似物及其使用方法 |
IT202000001567A1 (it) * | 2020-01-28 | 2021-07-28 | Univ Degli Studi Padova | Combinazione comprendente un composto bh3-mimetico e/o suoi sali o derivati farmaceuticamente accettabili e almeno un inibitore di pik3c3/vps34 e/o suoi sali o derivati farmaceuticamente accettabili, composizioni farmaceutiche che comprendano tale combinazione e uso nel trattamento dei linfomi non-hodgkin a cellule b e nel trattamento delle leucemie linfoidi e/o mieloidi. |
CN117083064A (zh) | 2020-11-25 | 2023-11-17 | 德西费拉制药有限责任公司 | 作为vps34抑制剂用于治疗病毒感染的吡啶基吡啶酮衍生物 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
TW225528B (ru) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
CA2224435C (en) | 1995-07-06 | 2008-08-05 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
US6096748A (en) | 1996-03-13 | 2000-08-01 | Smithkline Beecham Corporation | Pyrimidine compounds useful in treating cytokine mediated diseases |
JP3370340B2 (ja) | 1996-04-12 | 2003-01-27 | ワーナー―ランバート・コンパニー | チロシンキナーゼの不可逆的阻害剤 |
BR9709959A (pt) | 1996-06-24 | 2000-05-09 | Pfizer | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas |
CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
DE69942097D1 (de) | 1998-08-11 | 2010-04-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
IL154817A0 (en) | 2000-09-15 | 2003-10-31 | Vertex Pharma | Pyrazole derivatives and pharmaceutical compositions containing the same |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
ES2229928B1 (es) | 2003-10-02 | 2006-07-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirimidin-2-amina. |
EP1689722A2 (en) | 2003-10-10 | 2006-08-16 | Bayer Pharmaceuticals Corporation | 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders |
MXPA06004498A (es) | 2003-10-23 | 2006-06-20 | Pharmacia Corp | Compuestos de pirimidina para el tratamiento de inflamacion. |
EP1858882A1 (en) | 2005-03-10 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives for treatment of hyperproliferative disorders |
CA2609392A1 (en) | 2005-05-24 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
ATE551334T1 (de) | 2007-02-06 | 2012-04-15 | Novartis Ag | Pi3-kinase-hemmer und verfahren zu ihrer verwendung |
US8263585B2 (en) | 2007-05-04 | 2012-09-11 | Novartis Ag | Organic compounds |
TW200908984A (en) | 2007-08-07 | 2009-03-01 | Piramal Life Sciences Ltd | Pyridyl derivatives, their preparation and use |
WO2010068863A2 (en) | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
WO2010151747A1 (en) | 2009-06-26 | 2010-12-29 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimine compounds and methods of making and using same |
-
2011
- 2011-12-19 CA CA2822565A patent/CA2822565A1/en not_active Abandoned
- 2011-12-19 AU AU2011346567A patent/AU2011346567A1/en not_active Abandoned
- 2011-12-19 EP EP11811150.9A patent/EP2655340B1/en active Active
- 2011-12-19 KR KR1020137019068A patent/KR20130130030A/ko not_active Application Discontinuation
- 2011-12-19 WO PCT/IB2011/055772 patent/WO2012085815A1/en active Application Filing
- 2011-12-19 BR BR112013015449A patent/BR112013015449A2/pt not_active IP Right Cessation
- 2011-12-19 US US13/995,889 patent/US8685993B2/en active Active
- 2011-12-19 EA EA201390917A patent/EA201390917A1/ru unknown
- 2011-12-19 MX MX2013007336A patent/MX2013007336A/es not_active Application Discontinuation
- 2011-12-19 CN CN2011800618070A patent/CN103270026A/zh active Pending
- 2011-12-19 JP JP2013545602A patent/JP2014500308A/ja active Pending
-
2014
- 2014-02-05 US US14/173,072 patent/US8901147B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20140155402A1 (en) | 2014-06-05 |
AU2011346567A1 (en) | 2013-07-25 |
KR20130130030A (ko) | 2013-11-29 |
CA2822565A1 (en) | 2012-06-28 |
MX2013007336A (es) | 2013-08-01 |
WO2012085815A1 (en) | 2012-06-28 |
EP2655340A1 (en) | 2013-10-30 |
EP2655340B1 (en) | 2015-01-21 |
US8685993B2 (en) | 2014-04-01 |
US8901147B2 (en) | 2014-12-02 |
US20130338159A1 (en) | 2013-12-19 |
JP2014500308A (ja) | 2014-01-09 |
BR112013015449A2 (pt) | 2016-09-20 |
CN103270026A (zh) | 2013-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201390917A1 (ru) | Дигетероарильные соединения в качестве ингибиторов vps34 | |
EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
EA201391615A1 (ru) | Дейтерированные потенциаторы cftr | |
EA201101583A1 (ru) | Ингибиторы pi3 киназы или mtor | |
EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
EA201290191A1 (ru) | N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ | |
PH12014502733A1 (en) | Neprilysin inhibitors | |
EA201891553A1 (ru) | Ингибиторы syk | |
EA201690752A1 (ru) | Ингибиторы g12c kras | |
EA201490696A1 (ru) | 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантной idh | |
MY165087A (en) | Neprilysin inhibitors | |
EA201590224A1 (ru) | Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
EA201290632A1 (ru) | Производные бетулина | |
EA201370166A1 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
EA201500265A1 (ru) | Ингибиторы репликации вирусов гриппа | |
EA201390723A1 (ru) | Аминозамещенные производные бисфенилпентановой кислоты в качестве ингибиторов nep | |
EA201290919A1 (ru) | Индазольные соединения и их применение | |
MY170935A (en) | Neprilysin inhibitors | |
EA201490919A1 (ru) | Производные бетулина | |
EA201270752A1 (ru) | Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью | |
EA201491247A1 (ru) | Производные дигидробензооксазина и дигидропиридооксазина | |
EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
SG191175A1 (en) | Neprilysin inhibitors | |
EA201391288A1 (ru) | Производные пиразолоспирокетонов для применения в качестве ингибиторов ацетил-коа-карбоксилаз |